Taysha Gene Therapies (TSHA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Yanan Zhu from Wells Fargo maintained a Buy rating on the stock and has a $7.50 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Yanan Zhu’s rating is based on several key factors that indicate a positive outlook for Taysha Gene Therapies. The company has announced a favorable design for its pivotal study on Rett syndrome, which aligns with the FDA’s requirements. This alignment is crucial as it increases the likelihood of regulatory approval. The study’s design includes a primary endpoint that focuses on developmental milestone gains, which are significant indicators of the therapy’s efficacy.
Additionally, Taysha Gene Therapies has reported promising data from the dose-escalation portion of their study, achieving a 100% response rate for both low and high doses. This high efficacy rate, particularly the faster response in the high dose cohort, suggests strong potential for the therapy’s success. The use of extensive natural history study data to inform the study design further supports the robustness of their approach. These factors collectively contribute to Yanan Zhu’s Buy rating, reflecting confidence in the company’s future performance.
According to TipRanks, Zhu is an analyst with an average return of -6.8% and a 28.95% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Regulus, Ionis Pharmaceuticals, and Sarepta Therapeutics.
In another report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $7.00 price target.